Infant Bacterial Therapeutics (9IB) Stock Overview

Operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. More details

9IB fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Earnings have declined by 12.7% per year over past 5 years

Makes less than USD$1m in revenue (SEK0)

Does not have a meaningful market cap (€81M)

9IB Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW487,274 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

487,274 investors already sharing narratives

View all narratives

Infant Bacterial Therapeutics AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Infant Bacterial Therapeutics
Historical stock prices
Current Share Price	SEK 5.81
52 Week High	SEK 6.46
52 Week Low	SEK 3.91
Beta	0.35
1 Month Change	6.80%
3 Month Change	28.54%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-10.06%

Recent updates

Shareholder Returns

	9IB	DE Pharmaceuticals	DE Market
7D	-7.2%	-1.4%	-0.5%
1Y	n/a	44.2%	-2.1%

Return vs Industry: Insufficient data to determine how 9IB performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how 9IB performed against the German Market.

Price Volatility

Is 9IB's price volatile compared to industry and market?
9IB volatility
9IB Average Weekly Movement	7.8%
Pharmaceuticals Industry Average Movement	5.8%
Market Average Movement	5.5%
10% most volatile stocks in DE Market	12.7%
10% least volatile stocks in DE Market	2.8%

Stable Share Price: 9IB has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 9IB's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2011	6	Staffan Stromberg	www.ibtherapeutics.com

Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which has completed Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants.

Infant Bacterial Therapeutics AB (publ) Fundamentals Summary

How do Infant Bacterial Therapeutics's earnings and revenue compare to its market cap?
9IB fundamental statistics
Market cap	€80.50m
Earnings (TTM)	-€6.46m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-12.5x

P/E Ratio

Is 9IB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
9IB income statement (TTM)
Revenue	SEK 0
Cost of Revenue	SEK 0
Gross Profit	SEK 0
Other Expenses	SEK 71.36m
Earnings	-SEK 71.36m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

Aug 26, 2026

Earnings per share (EPS)	-5.30
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 9IB perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/09 02:42
End of Day Share Price	2026/07/09 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Infant Bacterial Therapeutics AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Infant Bacterial Therapeutics AB (publ)DB:9IB Stock Report